Blog

The Lancet: Causes of death shifting in people with HIV – The Gay UK

Posted: Sunday, July 20, 2014

The study which involved nearly 50 000 HIV-positive adults receiving care and antiretroviral therapy (ART) at more than 200 clinics across Europe, USA, and Australia found that overall death rates have almost halved since 1999, while deaths due to AIDS-related causes and cardiovascular disease have declined by around 65% and liver-related deaths by more than 50%. Although deaths from most causes declined over the study period, there was no reduction…

The Lancet: Causes of death shifting in people with HIV – Science Codex

Posted: Friday, July 18, 2014

HIV-positive adults in high income countries face a substantially reduced risk of death from AIDS-related causes, cardiovascular disease, and liver disease compared with a decade ago, according to a large international study published in The Lancet. The study which involved nearly 50 000 HIV-positive adults receiving care and antiretroviral therapy (ART) at more than 200 clinics across Europe, USA, and Australia found that overall death rates have almost halved since…

Personal View looks back on 40 years of the Glasgow Coma Scale – Medical Xpress

Posted: Tuesday, July 15, 2014

A group of leading brain injury specialists look back on 40 years of the Glasgow Coma Scale and outline the continuing role of the scale in research and clinical practice, in a new Personal View published in The Lancet Neurology. The Personal View is published on the 40th anniversary of the Glasgow Coma Scale’s introduction in a 1974 Lancet article*. Since this seminal publication, the Glasgow Coma Scale has provided…

Annals of Internal Medicine tip sheet for July 15, 2014, issue – Science Codex

Posted: Tuesday, July 15, 2014

Heart patients significantly more likely to stop taking medication after pill changes appearance When it comes to taking generic heart medications, appearance matters, according to a study published in Annals of Internal Medicine (http://www.annals.org/article.aspx?doi=10.7326/M13-2381). Physicians often prescribe generic medications for the treatment of cardiovascular disease because generics are inexpensive for patients and payors and are available in nearly every class of relevant medication – antihypertensive, lipid-lowering, anticoagulant, antiplatelet, and antiarrhythmic…

Pill appearance affects how patients take their medications – Science Codex

Posted: Tuesday, July 15, 2014

Heart patients significantly more likely to stop taking medication after pill changes appearance When it comes to taking generic heart medications, appearance matters, according to a study published in Annals of Internal Medicine (http://www.annals.org/article.aspx?doi=10.7326/M13-2381). Physicians often prescribe generic medications for the treatment of cardiovascular disease because generics are inexpensive for patients and payors and are available in nearly every class of relevant medication – antihypertensive, lipid-lowering, anticoagulant, antiplatelet, and antiarrhythmic…

QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in … – Virtual-Strategy Magazine (press release)

Posted: Monday, July 14, 2014

VANCOUVER, British Columbia, July 14, 2014 (GLOBE NEWSWIRE) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) today announced the publication of data from its Phase 1b proof-of-concept trial of QLT091001 in subjects with Leber Congenital Amaurosis (LCA) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT) in The Lancet. The peer-reviewed journal article is available first in the online edition of The Lancet at…

The Lancet: World’s most advanced dengue vaccine candidate shows promise … – Eureka! Science News

Posted: Sunday, July 13, 2014

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet. Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection. WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with…

New TB drug gets approval amid side effect concerns – eMaxHealth

Posted: Sunday, July 13, 2014

Privacy Policy | Disclaimer | About Us Editorial Review Process | Advertise | Contact | Contributors | Republish EmaxHealth Stories

The Lancet: World’s most advanced dengue vaccine candidate shows promise … – Eureka! Science News

Posted: Saturday, July 12, 2014

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet. Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection. WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with…

Lancet study finds alarming global rise in use of antibiotics – Sydney Morning Herald

Posted: Saturday, July 12, 2014

‘; var fr = document.getElementById(adID); setHash(fr, hash); fr.body = body; var doc = getFrameDocument(fr); doc.open(); doc.write(body); setTimeout(function() {closeDoc(getFrameDocument(document.getElementById(adID)))}, 2000); } function renderJIFAdWithInterim(holderID, adID, srcUrl, width, height, hash, bodyAttributes) { setHash(document.getElementById(holderID), hash); document.dcdAdsR.push(adID); document.write(”); } function renderIJAd(holderID, adID, srcUrl, hash) { document.dcdAdsAA.push(holderID); setHash(document.getElementById(holderID), hash); document.write(” + ‘ript>’); } function renderJAd(holderID, adID, srcUrl, hash) { document.dcdAdsAA.push(holderID); setHash(document.getElementById(holderID), hash); document.dcdAdsH.push(holderID); document.dcdAdsI.push(adID); document.dcdAdsU.push(srcUrl); } function er_showAd() { var regex = new RegExp(“externalReferrer=(.*?)(; |&|$)”, “gi”);…

The Lancet: World’s most advanced dengue vaccine candidate shows promise … – Eureka! Science News

Posted: Saturday, July 12, 2014

The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet. Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection. WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with…

The Lancet: Novel treatment for drug-resistant tuberculosis shows promise, but … – Science Codex

Posted: Friday, July 11, 2014

In a viewpoint published this week in The Lancet, the Community Research Advisors Group (CRAG) argue that research into bedaquiline – a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) – should proceed cautiously in people with drug-sensitive tuberculosis. CRAG, an international, community-based advisory board for the US Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium, writing in The Lancet independently, urge researchers to balance the goal of shortening…

Biotie: Tozadenant Phase 2b Parkinson’s disease study published in Lancet … – Virtual-Strategy Magazine (press release)

Posted: Wednesday, July 09, 2014

TURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) — Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson’s disease patients experiencing end of dose wearing off have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol…

The Lancet Global Health: Incidence of childhood tuberculosis could be 25 … – Science Codex

Posted: Wednesday, July 09, 2014

New estimates indicate that over 650 000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs)*—almost 25% higher than the total number of new cases worldwide estimated by WHO in 2012 (530 000)**. The research, published in The Lancet Global Health, also suggests that about 15 million children are exposed to TB every year, and roughly 53 million are living with…

Biotie: Tozadenant Phase 2b Parkinson’s disease study published in Lancet … – Virtual-Strategy Magazine (press release)

Posted: Tuesday, July 08, 2014

TURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) — Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson’s disease patients experiencing end of dose wearing off have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol…

Biotie: Tozadenant Phase 2b Parkinson’s disease study published in Lancet … – Virtual-Strategy Magazine (press release)

Posted: Tuesday, July 08, 2014

TURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) — Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson’s disease patients experiencing end of dose wearing off have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol…